THERAPY DOSSIER · th-883dee0092e4

Oxymatrine

Nutraceutical · Quinolizidine alkaloid from Sophora; no ChEMBL mechanism record.

Evidence & regulatory context

Mechanism: Quinolizidine alkaloid from Sophora; no ChEMBL mechanism record.
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL458337 ↗
ChEMBL max phase: -1 / 4 (development scale, not regulatory approval)
Synonyms: Oxymatrine
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02202473 ↗PHASE4completed

Oxymatrine Plus Lamivudine vs Lamivudine in Chronic Hepatitis B

Chronic Hepatitis B

Enrolment: 192 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31840202 ↗2019Reported benefit

Protective effect of Oxymatrine against acute spinal cord injury in rats via modulating oxidative stress, inflammation and apoptosis.

RatSpinal cord injuryUnspecifiedSprague-Dawleymale

Model: Acute spinal cord injury in rats

Oxymatrine improved motor function recovery and reduced oxidative stress, inflammation and apoptosis after acute spinal cord injury in rats.

Extraction: extract · Supplied extraction confidence: 0.45. Machine-extracted fields require source verification.

Loading the evidence…